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ABSTRACT
Lower vertebrates, such as newt and zebrafish, retain a robust cardiac regenerative capacity following
injury. Recently, our group demonstrated that neonatal mammalian hearts have a remarkable
regenerative potential in the first few days after birth. Although adult mammals lack this regenerative
potential, it is now clear that there is measurable cardiomyocyte turnover that occurs in the adult
mammalian heart. In both neonatal and adult mammals, proliferation of pre-existing cardiomyocytes
appears to be the underlying mechanism of myocyte turnover. This review will highlight the advances
and landmark studies that opened new frontiers in cardiac regeneration.
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this work.INTRODUCTION
Cardiovascular disease is the leading cause of morbidity and mortality in the developed world.
1
Thus, numerous attempts at unraveling the regenerative potential of the mammalian heart have been
pursued.
2 Earlier advancements on the regenerative capabilities of lower organisms have paved the
road for a new understanding of the ability of the mammalian heart to regenerate following injury.
Recent evidence identified an inherent regenerative capacity of the mammalian heart during the
neonatal period, resembling their evolutionary ancestors.
3–5 Here, we will discuss the recent rapid
advancements in the heart regeneration field, with focus on cardiomyocyte proliferation.
REGENERATION IN LOWER VERTEBRATES
Tissue regenerative capacity varies widely between species, with some lower organisms displaying
a remarkable ability to regenerate various organs and extremities. For example, adult zebrafish
effectively regenerate multiple organs and structures, including amputated fins, injured retinae,
transected optic nerves and spinal cord.
6–8Zebrafish also displays a robust natural capacity for heart
regeneration, making it a very useful model system.
9,10 Zebrafish heart regeneration was studied by
examining the effects of removing 20% of the ventricle by surgical resection. This resulted in an initial
fibrotic response, and cardiomyocyte proliferation within first two week following amputation. This was
followed by complete regeneration within 60 days post-injury.
10 To address the source of the newly
formed cardiomyocytes, genetic fate-mapping studies were performed to trace the lineage of
cardiomyocytes using the Cre/lox system. These studies demonstrated that the vast majority of heart
muscle cells formed during the process of zebrafish heart regeneration arise from proliferation of the
pre-existing cardiomyocytes, rather than progenitor cells.
11,12
Since then several zebrafish cardiac injury models, that yield distinct outcomes of myocardial
regeneration, have been described. For example, the infarct models of zebrafish after cryoinjury to the
ventricular apex, resulted in necrosis of approximately 25% of ventricular tissue, followed by myocyte
proliferation and regeneration of heart within 130 days post injury.
13,14 However, perfect ventricular
shape was not restored, which highlights the heterogeneity of the regenerative response after different
types of injury. In addition, Wang and colleagues generated an elegant Z-CAT (zebrafish cardiomyocyte
ablation transgene) model using a 4-hydroxytamoxifen (4-HT)–inducible Cre recombinase (CreER)
system to facilitate cell type–specific ablation. Intriguingly, the mechanism of regeneration in all of
these models was myocyte proliferation despite the varying degrees of cell death and regenerative
response (Table 1). Moreover, recent hypoxic cardiac injury models in zebrafish also demonstrated
evidence of cardiac oxidative stress, inflammation, and proliferation; which mimics ischemic injury in
mammalian heart.
15,16 Ultimately, in these models of heart regeneration, cardiomyocyte proliferation
was the key mediator of the regenerative process.
Table 1. Cardiac Regenerative Capacity in Different Models.
Injury 
Myocardial Infraction/
Ischemia-reprefusion
No regeneration
Outcome
Amputation Regeneration within by 21 days
Cryoinjury Delayed regeneration > 130 days
Amputation
Myocardial Infraction
Apical resection Regeneration within by 60 days
Liquid nitrogen cooled probe 
Model
Z-CAT Cardiomyocyte  ablation 
Apical resection
Regeneration within 30–45 days
LAD-ligation at P1 Regeneration by 21 days
Cryoinjury
No regeneration
Liquid nitrogen cooled probe 
Myocardial Infraction
Outline of cardiac regenerative potential of zebrafish, neonatal and adult mouse hearts following various types of injury.
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brain, and heart.
17–22 The newt heart was one of the first models of heart regeneration described.
23
As in zebrafish, myocyte proliferation appears to be the underlying mechanism of newt heart
regeneration.
24 More recently, resection injuries at the base of the newt heart has been reported to
completely regenerate,
25 providing a good model of complete myocardial regeneration. These
pioneering studies in lower vertebrates indicate that activating cardiomyocyte proliferation is the key
mediator of heart regeneration.
NEONATAL HEART REGENERATION
In contrast to lower vertebrates, adult mammalian heart cardiomyogenesis is very limited and is
insufficient to restore normal cardiac function following injury. Studies in the late 1990s elegantly
mapped the DNA synthesis and cell cycle dynamics of the mammalian heart during development and
after birth,
26 where they showed that DNA synthesis drops significantly around birth with low-level DNA
synthesis few days after birth. Around P5 to P7, cardiomyocytes undergo a final round of DNA synthesis
that correspond to binucleation, and the majority of cardiomyocytes then permanently exit the cell
cycle (Figure 1A). Therefore, due to the similarities between the immature mammalian heart and lower
vertebrates (Table 1),
9,27 it became important to determine whether higher mammals have similar
regenerative abilities.
Recently, we demonstrated that removal of up to 15% of the apex of the left ventricle of postnatal day
1 (P1) mice results in complete regeneration within three weeks without any measurable fibrosis and
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Figure 1. Proliferative Window of Postnatal Cardiomyocytes A) Cardiomyocyte DNA synthesis (left index)
significantly drops around birth with low-level synthesis few days after birth with corresponding increase in the
binucleation (right index) (Adapted from Soonpaa et al.
26). This correlates with the cardiac growth being
hyperplastic and hypertrophic before and after birth respectively (lower panel). E, embryonic; P, postnatal days.
B) Schematic of neonatal heart 21 days post myocardial regeneration (MI) at P1 showing complete full thickness
regeneration with minimal fibrosis (blue), while decreased regenerative capacity following MIs induced at P7,
and no detectable regeneration with more fibrosis following MIs induced at P14 was seen (lower panel).
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3 This response was well characterized by an early transient extracellular matrix
deposition, and a robust cardiomyocyte proliferation with gradual restoration of normal cardiac
morphology. Fibrotic scarring and hypertrophy, both typical hallmarks of the injured adult mammalian
heart, were absent in the neonatal heart following regeneration. In addition to the histological evidence
of proliferating myocytes, genetic fate-mapping studies confirmed that the majority of newly formed
cardiomyocytes are derived from the proliferation of preexisting cardiomyocytes.
3 This robust
regenerative response occurred in the brief window of time after birth during which cardiomyocytes are
mononucleated and are able to proliferate. However, this regenerative capacity is lost by P7, after
which injury results in the typical cardiomyocyte hypertrophy scar-formation characteristic of the adult
mammalian heart. Not surprisingly, loss of this regenerative potential coincides with the binucleation
and cell cycle exit of cardiomyocytes.
26,27
More recently, we established an ischemic injury model where the left anterior descending coronary
artery was ligated in P1 neonates.
5 The injury response was similar to the resection model, with robust
cardiomyocyte proliferation throughout the myocardium, as well as restoration of normal morphology
and systolic function (Figure 1B). This regenerative phenomenon provides an invaluable tool for
unraveling the molecular networks that regulate mammalian heart regeneration, and the mechanism of
post-natal cardiomyocyte cell cycle arrest. Insights from this transition could provide important clues
on how to reactivate myocyte cell cycle in the adult heart.
This close temporal relationship between cardiomyocyte proliferation and heart regeneration
amongst animals raises the question about the extent of cardiomyocyte proliferation in humans.
During postnatal development, the human heart was believed to grow in size through cardiomyocyte
hypertrophy rather than cardiomyocyte hyperplasia. However, recent studies showed that
cardiomyocyte proliferation contributes to developmental heart growth in young humans.
28 This report
showed that the percentages of cardiomyocytes in mitosis were highest at 0.04% in infants and
decreased to 0.009% by 20 years. Similarly, cytokinesis of cardiomyocytes decreases from 0.016% at
birth to 0.005% by adolescent humans and completely absent in adults. Interestingly, the number of
cardiomyocytes in the left ventricle increased by 3.4 fold from birth to over a period of 20 years of life,
which intriguingly was consistent with measured cardiomyocyte cell cycle activity.
28 Clinical studies
have also shown that in newborns who underwent surgical repair of the anomalous left coronary artery
(LCAPA) showed that the majority of improvement in their ejection fraction occurred when the defect
was corrected in the first 3 months following birth, but not after.
29 This suggests that myocyte
hyperplasia may play a role in the ability of the infant heart to recover. Together, these studies imply
that infants may in fact be capable of regenerating myocardial tissue following injury, and that
stimulating cardiomyocyte proliferation would be a promising approach for older patients.
MYOCYTE TURNOVER IN ADULT MAMMALIAN HEART
In sharp contrast to lower vertebrates and neonatal mammals, the adult mammalian heart has a
limited regenerative capacity following injury and responds to cardiac tissue damage by scarring.
However, over the past decade, it has become clear that the adult mammalian heart is not a terminally
differentiated organ, and that there is constant cardiomyocyte turnover occurring within the adult
mammalian, murine and human hearts throughout life.
30–34
Cardiomyocyte turnover in the murine heart was established through quantitative studies of DNA
synthesis using autoradiographic measurement, which indicated that turnover rates of cardiomyocytes
are around 0.0006% in uninjured hearts, while following injury the rate was 0.0083%.
35,36 This
mapping of the limited, but measurable ability of adult murine cardiomyocytes to enter the cell cycle
generated a promising potential for therapeutic manipulation of these proliferative cardiomyocytes.
Similarly, several other reports have documented the formation of new cardiomyocytes in the human
heart. Data from the nuclear fallout during the cold war by using
14C dating to measure cardiomyocyte
age indicated that turnover rates of cardiomyocytes are about 1% per year at the age of 20 years.
30
These rate further decreases to 0.4% around 75 years of age, and approximately 45% of
cardiomyocytes are replaced over the normal human lifespan.
30
These findings suggested that the adult mammalian heart maintains a measurable capacity for
cardiomyocyte turnover throughout life, which provides a rationale for manipulating the cell cycle
activity of cardiomyocytes as a strategy for myocardial regeneration. However, several questions
needed to be addressed; in particular, identifying the source of newly formed cardiomyocytes, and
whether this inherent capacity can be augmented to replenish lost cardiomyocytes.
Page 215 of 221
Muralidhar et al. Global Cardiology Science and Practice 2013:29Recently, a landmark study described the dynamics of cardiomyocyte turnover in the adult
mammalian heart.
37 Senyo and colleagues adapted a novel multi isotope mass spectrometry (MIMS)
analysis to have better understanding of the origin and regeneration rate of cardiomyocytes in the
adult murine heart. By using nonradioactive stable nitrogen isotope
15N label that marks DNA of cells
undergoing mitosis, they showed that in young adult mice, the cardiomyocyte turnover rate per year
was 0.76%, and this turnover rate decreases with aging mice. Intriguingly, this is similar to the
cardiomyocyte turnover dynamics described previously in humans
30. More importantly, since
cardiomyocytes can replicate their DNA without completing the cell cycle and resulting in polyploidy
and multinucleation as has been previously shown
38; the authors show that a higher number of the
15N
þ cardiomyocytes are diploid, indicative of cell division in the uninjured adult heart. In addition,
analysis of GFP labeled cardiomyocytes and genetic fate mapping studies in double transgenic
MerCreMer/ZEG mice on induction with 4-OH-tamoxifen showed that the newly formed cardiomyocytes
are derived from preexisting cardiomyocytes, in both during aging and following myocardial infarction.
Interestingly, the authors showed an increase in cardiomyocyte proliferation at the border zone
following myocardial infarction, in contrast to a previous study that showed increased ploidy rather
than cell division
39. The authors do not exclude the possibility that a progenitor population contributed
to the newly formed cardiomyocytes following injury through differentiation without proliferation,
which might explain earlier confounding results
40. Therefore, conclusive genetic fate mapping studies
suggest that pre-existing cardiomyocytes are indeed the source of cardiomyocyte turnover in both the
neonatal and adult hearts, which sets the stage for therapeutic strategies aimed at manipulating
cardiomyocyte cell cycle as a strategy for heart regeneration.
FORCED CARDIOMYOCYTE PROLIFERATION IN MOUSE
Lower vertebrate cardiomyocytes are smaller in size and mononucleated with less myofibrils that ease
cell cycle reentry following injury.
41 In contrast, mammalian cardiomyocytes mainly proliferate during
embryonic development and a short period after birth. Following postnatal switch, cardiomyocytes
turnover at an extremely low rate as described above and cardiac hypertrophy becomes the major
growth mechanism of cardiomyocytes.
The mammalian cell cycle is tightly regulated by a combination of positive and negative regulators
such as cyclins, cyclin-dependent kinases (CDKs), CDK inhibitors (CDKIs), CDK activating kinase (CAK)
and the E2F family of transcription factors. Cyclin/CDK complexes show a periodic accumulation and
degradation pattern, and require activation by CAKs through phosphorylation.
42–45 Induction of cell
cycle progression by Cyclin-D/CDK4-6 and Cyclin-E/CDK2 complexes allow progression through G1/S
transition phase. Cyclin-E/CDK2 complex play a significant role in the phosphorylation of Rb and
activation of E2F transcription factors for cell cycle progression. However, these two complexes
are under regulation of CDKIs such as Cip/Kip family (p21
Cip1, p27
Kip1, p57
Kip2) and Ink4 family
(p15
Ink4b, p16
Ink4a, p18
Ink4c, p19
Ink4d) which directly bind and inhibit cyclin-D/E/A dependent kinases
and CyclinD-CDK4/6 complex respectively.
30,46 One other important role of the Cyclin-D/CDK4-6
complex in addition to activation of E2F is sequestering p21, thereby preventing its interaction with
Cyclin-E/CDK2 complex and which inhibits cell cycle progression.
In adult mammalian hearts, cardiomyocytes show increased levels of CDKIs and decreased activity of
positive regulators of cell cycle.
47–52 Henceforth, reactivation of the cardiomyocyte cell cycle is
possible by suppression of cell cycle inhibitors or by over-expressing cell cycle activators.
Over-expression studies of viral oncoprotein SV40 T-Antigen, known to stimulate entry of quiescent or
differentiated cells into S phase, induced continuous cycling of cardiomyocytes in both embryonic and
adult hearts.
53,54 Similarly, transgenic mice over-expressing cell cycle regulators such as Cyclin D2,
Cyclin A4 and Cyclin D1 in postnatal heart also demonstrate evidence of mitosis and induction of
CDK2/4 levels associated with DNA synthesis.
26,55–59 In addition, improved cardiac function after MI
was detected following overexpression of the cell cycle activator Cyclin D2 in cardiomyocytes.
56
Conversely, deletion of CDKI p27
Kip1 or immunodepletion of p21
Cip1 in cardiomyocytes is associated
with a trend towards progression to S-phase.
47,48 Furthermore, E2F-1, which plays important role in cell
cycle control, has been shown to induce cardiomyocyte DNA synthesis in vitro and in vivo.
60
Studies have also demonstrated induction of cardiomyocyte cell cycle in vivo in response to
mitogens such as periostin, neuregulin-1, and FGF1, a response that seems to be limited to a
subpopulation of mononucleated cardiomyocytes.
61–64 Although, some of the effects of periostin on
cell cycle could not be reproduced.
65 More recently, activation of the evolutionary conserved Hippo
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postnatal proliferative window in mice.
66–68 Thus, the approach to coax adult cardiomyocytes to
reenter the cell cycle holds a lot of potential for cardiac regeneration.
While these important studies demonstrated proof of principal that induction of myocyte cell cycle is
possible, the molecular mechanisms responsible for postnatal cardiomyocyte cell cycle arrest
remained unclear. Recently we identified the bHLH transcription factor Meis1 as a key transcriptional
regulator of the cardiomyocyte cell cycle upstream of two synergistic CDKI inhibitors (p21, p16). Meis1
mRNA levels, and nuclear localization significantly increase in cardiomyocytes at the time of cell cycle
arrest (Figure 2). Moreover, Meis1 deletion in mouse cardiomyocytes is sufficient for extension of the
postnatal proliferative window of cardiomyocytes, and for re-activation of cardiomyocyte mitosis in the
adult heart with no deleterious effect on cardiac function.
69 In addition, Meis1 KO results in
upregulation of Ccnd2, MCM3, Chek1 and downregulation of APbb1, TP53, Gpr132, all of which have a
critical role in cell cycle regulation. Although the mechanism of activation of Meis1 in the postnatal
heart is not fully understood, these findings provide evidence for the possibility of reactivating dormant
regenerative programs in adult mammals at the molecular level that can be potential therapeutic
targets. Most importantly, rigorous analysis is required to identify the evolutionary advantages for
cardiomyocyte cell cycle exit, and to what extent can we harness the benefits of cardiomyocyte
proliferation.
MicroRNAs and Cardiomyocyte Proliferation
MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression by repression of their
target gene transcripts.
70 Although miRNAs are fine tuners of gene expression, they can target multiple
members of a common pathway and thus regulate multiple biological processes. Thus, searching for
miRNAs that regulate cardiomyocyte cell cycle has been pursued.
71 Members of the miR-15 family were
identified as being highly upregulated during the postnatal period when mammalian cardiomyocytes
binucleate and become terminally differentiated.
72 Myocardial-specific overexpression of miR-195,
a member of the miR-15 family, decreased cardiomyocyte proliferation,
72 and inhibits neonatal heart
regeneration.
5 In addition, pharmacological inhibition of miR-15 family members using LNA-modified
antimiRs at birth until adulthood increases cardiomyocyte proliferation and improved left ventricular
G0  M
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G1
M
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G1
M
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S
G1
Quiescence Arrest Active
Cell cycle
Meis1 localization Perinucleus Nucleus Nucleus
Age P1 P14 P7 P14
Meis1–/– knockout
M
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S
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PROLIFERATION PROLIFERATION PROLIFERATION PROLIFERATION
Figure 2. Meis1 Regulates Cardiomyocyte Cell Cycle Arrest Expression profile of Meis1 demonstrates perinuclear
in P1, nuclear localization at P7 and P14 cardiomyocytes that corresponds to active cell cycle in P1 and arrest in
P7 and P14. Conversely, this is switched in P14 Meis1 knock out models with reactivation of cell cycle and
myocyte proliferation.
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5 Protection from I/R injury and reduced
apoptosis was also observed following antimiR administration in adult mice.
73 Similarly, miRNAs
regulate zebrafish heart regeneration, where miR-133 was shown to be downregulated during
regeneration,
74 while overexpression of miR-133 reduced cardiomyocyte proliferation and inhibited
zebrafish cardiac regenerative. These data combined indicate that miRNAs may be negative regulators
of cardiomyocyte proliferation and heart regeneration.
Conversely, some miRNAs were found to be positive regulators of heart regeneration. To identify
miRNAs that induce cardiomyocyte proliferation, a large-scale screen representing 988 mature miRNAs
was performed that could specifically enhance the proliferation of neonatal rodent cardiomyocytes
in vitro.
75 Surprisingly, more than 40 miRNAs that could independently trigger cardiomyocyte mitosis
were identified.
75Ofthese miRNAs, miR-199a andmiR-590 were showntoinduce cell-cycle re-entry and
cytokinesis of adult cardiomyocytes in vitro. In addition, in vivo induction of miR-199a as well as
miR-590 in the heart by adeno-associated viruses led to increased cardiomyocyte proliferation, and
improvement of function following myocardial infarction. A more recent study identified the miR-17-92
cluster as another positive regulator of cardiomyocyte proliferation in postnatal and adult hearts.
76
Deletion of miR-17-92 reduces cardiomyocyte proliferation in embryonic, postnatal and adult stages. In
addition, overexpression of miR-17-92 increases adult cardiomyocyte proliferation and improved heart
function following injury. These studies suggest that stimulating cardiomyocyte proliferation is a
powerful tool for replacement of lost myocardium following injury.
CONCLUDING REMARKS
The cardiac regeneration field has evolved rapidly over the past two decades. Although it was
previously thought that the heart was a post mitotic organ, it is now clear that there is measurable
myocyte turnover that occurs in the adult mammalian and human hearts. The excitement created by
the realization that the heart is not a terminally differentiated organ has undoubtedly created a gold
rush approach to cardiac regeneration therapy. While the mechanism of myocyte turnover in the adult
mammalian heart is not well understood, a plausible strategy to achieve the elusive goal of cardiac
regeneration may lie within cardiomyocytes themselves. It is important here to draw a distinction
between the endogenous regenerative capacity of the myocardium, and the prospect of cell therapy as
a treatment for systolic dysfunction, which may activate alternative repair mechanisms. The studies
discussed in this review leave little doubt that pre-existing cardiomyocytes are indeed the source of
cardiomyocyte turnover in lower vertebrates as well as neonatal and adult hearts, and have become a
major focus of cardiac regenerative medicine (Figure 3). These studies have opened the door for
exploration of future therapeutic strategies focused on harnessing the power of myocyte proliferation
for heart regeneration. One critical question, which likely holds the key to heart regeneration,
Infarct
Cardiomyocyte Cell Cycle Re-Entry
(Transcription Factors,
Growth Factors, or miRs)
Injury
Figure 3. Endogenous Heart Regeneration Schematic of endogenous cardiac regenerative mechanism, which
occurs through proliferation of preexisting cardiomyocytes. Future therapeutic strategies could focus on a
number of pathways to enhance this phenomenon through maniplulation of direct cell cycle regulators,
transcription factors, growth factors or microRNAs.
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remarkable regenerative capacity shortly after birth?
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